4 assets in Epstein-Barr Virus-Associated Mesenchymal Tumor

Therapeutic assets addressing Epstein-Barr Virus-Associated Mesenchymal Tumor, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Tabelecleucel Epstein-Barr Virus-Associated Mesenchymal Tumor	Pierre Fabre Medicament	P2	CCC (53)
Pembrolizumab Epstein-Barr Virus-Associated Mesenchymal Tumor	Viracta Therapeutics, Inc.	P1	CC (43)
Valganciclovir Epstein-Barr Virus-Associated Mesenchymal Tumor	Viracta Therapeutics, Inc.	P1	CC (43)
Nanatinostat Epstein-Barr Virus-Associated Mesenchymal Tumor	Viracta Therapeutics, Inc.	P1	C (37)